Medical Oncologist
Targeted treatment
Adjuvant olaparib after surgery for BRCA carriers
For people with an inherited BRCA mutation and high-risk, HER2-negative early breast cancer, a year of olaparib after surgery and chemotherapy lowers recurrence and improves survival. This page explains, in general terms, who qualifies, where it fits and what taking it involves.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why is olaparib given after surgery to some BRCA carriers?
- Where olaparib usually fits in treatment
- What people most often notice on olaparib
- The vocabulary, in plain language
- What adjuvant olaparib offers, and its limits
- How a BRCA result affects the rest of your care
- Living with a year of olaparib
- Understanding whether you qualify
- Coping with a BRCA diagnosis alongside cancer
- Keeping treatment safe through the year
- What people assume about olaparib after surgery
- Common questions about adjuvant olaparib
The short answer
Why is olaparib given after surgery to some BRCA carriers?
For people with an inherited BRCA1 or BRCA2 mutation and high-risk, HER2-negative early breast cancer, a year of olaparib tablets after surgery and chemotherapy has been shown to lower the chance of the cancer returning and to help people live longer. Olaparib is a PARP inhibitor. It targets cancer cells that already have faulty DNA repair because of the BRCA mutation, making it harder for any remaining cancer cells to survive. It is taken alongside hormone therapy if the cancer is also hormone-sensitive.
Who is usually considered
People with a confirmed inherited BRCA mutation whose cancer carried a higher risk of returning. This includes triple negative cancers that remained after chemotherapy before surgery, or that were larger or node-positive, and hormone-sensitive cancers with high-risk features.
What treatment involves
Olaparib tablets twice a day for a year, starting after chemotherapy, surgery and usually radiation, with regular blood tests to check counts.
Who may not be suitable
People without an inherited BRCA mutation, those with lower-risk cancers, or those with significant bone marrow problems. Genetic testing is needed first.
This page gives general information only. Whether olaparib suits you is a decision for your oncologist.The pathway
Where olaparib usually fits in treatment
A common sequence. Your plan may be arranged differently.
-
Genetic testing
Ideally done early after diagnosis, so the result can guide surgery and later treatment.
-
Chemotherapy
Given before or after surgery, depending on the cancer.
-
Surgery and radiation
The cancer is removed, and radiation is given if needed.
-
A year of olaparib
Tablets twice daily, with blood tests, usually starting a few weeks after other treatment ends.
-
Hormone therapy if relevant
For hormone-sensitive cancers, hormone therapy runs alongside and continues for years.
Side effects
What people most often notice on olaparib
Many can be managed with simple measures and dose adjustments.
Feeling sick
Common early on. Taking tablets with food and anti-sickness medicine help.
Tiredness
Often linked to a low haemoglobin. Blood tests help find the cause.
Pace yourself and rest.Low blood counts
Red cells, white cells and platelets can fall. Dose pauses usually let them recover.
Taste changes and headaches
Usually mild and often improve with time.
Report promptly
- Fever or infection
- Unusual bruising or bleeding
- New breathlessness or cough
Words you will hear
The vocabulary, in plain language
- Adjuvant
- Treatment after surgery to lower recurrence risk.
- Olaparib
- A PARP inhibitor tablet.
- Germline BRCA mutation
- An inherited BRCA gene change present throughout the body.
- Residual disease
- Cancer still present at surgery after chemotherapy.
- CPS+EG score
- A scoring system sometimes used to judge risk in hormone-sensitive cancers after treatment before surgery.
- Invasive disease-free survival
- Time without invasive cancer returning.
Being straight with you
What adjuvant olaparib offers, and its limits
For eligible BRCA carriers, a year of olaparib after standard treatment is one of the clearer examples of targeted treatment improving outcomes in early breast cancer. It lowers the chance of recurrence and has been shown to improve survival. It does not remove the risk entirely.
Timely genetic testing matters
Because olaparib depends on a confirmed mutation, delays in genetic testing can delay treatment. Ask about testing early if you meet the criteria.
A year is a meaningful commitment
After chemotherapy, surgery and radiation, another year of tablets and blood tests can feel tiring. Dose adjustments help most people complete it.
Cost and access
Olaparib is expensive. Ask your team about availability, insurance and support programmes before starting.
What this page cannot tell you
It cannot tell you whether you qualify or how much benefit you would gain. Ask your oncologist.
Beyond olaparib
How a BRCA result affects the rest of your care
A BRCA mutation influences decisions beyond medicines, both for you and for your relatives.
Surgery choices
Some women with a BRCA mutation choose mastectomy, sometimes of both breasts, to lower the risk of a new cancer. This is a personal decision made with your surgeon.
Ovarian cancer risk
BRCA carriers have a higher risk of ovarian cancer, and removal of the ovaries and tubes is usually recommended at an appropriate age after childbearing.
Family members
Relatives can be offered testing. Those who carry the mutation may choose extra screening or preventive options.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Daily life
Living with a year of olaparib
Olaparib is taken at home, allowing many people to return to work and family life while on treatment.
Establish a routine
Take tablets at the same times each day with food. A pill organiser and phone reminders help.
Stay active
Gentle exercise improves energy and mood, and helps recovery after earlier treatment.
Check new medicines
Some antibiotics, antifungals and herbal products interact with olaparib. Ask before starting anything new.
Eligibility
Understanding whether you qualify
The study that established adjuvant olaparib included people with specific high-risk features. Your oncologist uses similar criteria to judge whether the benefit is likely to be meaningful for you.
A confirmed inherited mutation
The BRCA1 or BRCA2 change must be inherited, found on a blood or saliva test, rather than only in the tumour. Tumour-only changes are handled differently, so it is important to know which test was done.
Triple negative cancers
If chemotherapy was given before surgery, cancer remaining in the breast or lymph nodes at surgery usually qualifies. If surgery came first, larger tumours or lymph node involvement usually qualify.
Hormone-sensitive cancers
Higher-risk criteria apply, such as several involved lymph nodes, or remaining cancer with high-risk features after chemotherapy before surgery.
Timing
Olaparib is usually started within a few months of finishing chemotherapy, surgery and radiation, so it is worth confirming genetic test results and eligibility early.
Coping
Coping with a BRCA diagnosis alongside cancer
Learning that you carry a BRCA mutation at the same time as treating breast cancer can feel overwhelming. It raises questions about the future, children and relatives.
Take it step by step
Focus first on your current treatment. Decisions about risk-reducing surgery and family testing can often be made later, with time to think.
Use genetic counselling
Counsellors help you understand what the result means, talk to relatives and plan screening or preventive options at a pace that suits you.
Find support
Support groups for BRCA carriers can offer practical advice from people who have faced the same choices.
Monitoring
Keeping treatment safe through the year
Regular checks allow side effects to be caught early and doses adjusted before problems become serious.
Blood counts
A full blood count is checked before starting and regularly during treatment. Falling haemoglobin, white cells or platelets may lead to a pause or lower dose.
Reporting symptoms between tests
Unusual tiredness, breathlessness, frequent infections, easy bruising or bleeding can signal falling counts. Tell your team promptly rather than waiting for the next scheduled blood test.
Long-term blood checks
If counts stay low after a pause, further tests may be arranged to rule out rare bone marrow problems.
Commonly believed
What people assume about olaparib after surgery
Everyone with triple negative breast cancer gets olaparib.
It is only for people with an inherited BRCA mutation and high-risk cancer.
A family history is enough to qualify.
A confirmed BRCA mutation on genetic testing is needed.
Olaparib replaces hormone therapy.
For hormone-sensitive cancers, hormone therapy continues alongside and after olaparib.
Stopping for low counts means I have failed treatment.
Pauses and dose reductions are common and help people complete the year.
Questions we are asked
Common questions about adjuvant olaparib
When should genetic testing be done?
Ideally soon after diagnosis, so results can guide surgery and treatment. Ask your oncologist if you have not been tested.
Can I take olaparib with radiation?
It is usually started after radiation is complete. Your team will plan timing.
How often are blood tests needed?
Usually monthly, and more often at the start.
Does olaparib affect fertility?
Pregnancy is unsafe during treatment. Discuss fertility and contraception with your team.
Can men take adjuvant olaparib?
Men with BRCA-related high-risk early breast cancer may be considered. Ask your oncologist.
What if I cannot afford it?
Tell your team early. Support programmes, insurance or schemes may help.
Will my relatives be tested?
They can choose testing after genetic counselling. Your result helps target their test.
Where can I read about my own drug?
Your oncology team will give you written information about your treatment. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- New England Journal of Medicine — Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer (OlympiA)
- National Cancer Institute — BRCA gene changes: cancer risk and genetic testing
- Cancer Research UK — Olaparib (Lynparza)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.